Key Takeaways
- Ravi Kumar, CEO of Cognizant Technology Solutions Corp. (CTSH), received an estimated total compensation of $21.5 million in 2025, up 22 % from roughly $16.8 million in 2024.
- Over the past six months, CTSH insiders executed 21 sales (no purchases), moving a combined ≈ 76,480 shares worth about $5.4 million; the CEO alone sold 6,075 shares for ≈ $501 k.
- Members of Congress traded CTSH twice in the same period—one purchase and one sale—indicating limited legislative interest.
- Institutional investors showed mixed sentiment: 484 funds added shares while 480 reduced positions; notable moves include a massive ‑75.8 % reduction by UBS AM and a +inf% (new) addition by GQG Partners.
- Analyst coverage is uniformly positive: four firms issued buy/overweight ratings, with zero sell ratings; the median 6‑month price target stands at $83.0.
- Individual price targets range from $61.0 (Wedbush) to $88.0 (RBC Capital), reflecting a modest upside potential relative to the current trading level.
- The data are derived from a recent DEF14A filing and various Quiver Quantitative dashboards; readers should treat the figures as estimates and consult original sources for precise numbers, as parsing errors may occur.
Executive Compensation Overview
The latest DEF14A filing submitted to the SEC on April 17, 2026 reveals that Ravi Kumar Singisetty, Chief Executive Officer of Cognizant Technology Solutions Corp. (ticker: CTSH), earned an estimated $21,532,448 in total compensation for fiscal year 2025. This figure marks a 21.97 % increase from the prior year’s estimated compensation of $16,801,707 in 2024. The jump reflects a combination of base salary, performance‑based bonuses, stock awards, and other incentive components that are typical for a large‑scale IT services leader navigating a competitive market. While the filing provides the aggregate amount, detailed breakdowns of each pay component are not included in the excerpt; however, the year‑over‑year growth suggests that the board rewarded Kumar for achieving strategic milestones, such as revenue expansion, margin improvement, or successful execution of transformation initiatives.
Insider Trading Activity Breakdown
Insider trading patterns over the last six months reveal a clear selling bias among CTSH executives and directors. A total of 21 transactions were recorded, all of which were sales with zero purchases. The aggregated volume amounts to approximately 76,480 shares, translating to an estimated proceeds of $5.4 million. Notable contributors include Michael Patsalos‑Fox, who offloaded 25,000 shares (~$2.1 million); Surya Gummadi (President – Americas) sold 22,728 shares (~$1.8 million); John Sunshine Kim (CLO, CAO & Corporate Secretary) disposed of 10,000 shares (~$0.8 million); CEO Ravi Kumar himself sold 6,075 shares (~$0.5 million); and Alina Kerdman (SVP, Controller & CAO) moved 767 shares (~$54 k). The uniform absence of insider purchases may signal that those closest to the company perceive the current stock price as relatively fair or even slightly overvalued, prompting them to realize gains or reallocate personal portfolios.
Congressional Stock Trading
Legislative engagement with CTSH remains minimal. In the same six‑month window, members of Congress executed exactly two trades—one purchase and one sale—resulting in a net neutral position. The specific details of those trades (e.g., exact share counts, prices, or timing) are not disclosed in the summary, but the balanced nature suggests that any legislative interest is modest and likely driven by individual portfolio management rather than a coordinated stance on the company. This low level of activity contrasts with sectors that often attract heightened congressional scrutiny, such as defense, energy, or pharmaceuticals.
Hedge Fund Institutional Activity
Institutional sentiment toward CTSH shows a split‑decision picture. Over the most recent quarter, 484 funds increased their holdings, while 480 funds decreased theirs, indicating near‑equilibrium between bullish and bearish stances. Some of the most pronounced moves include:
- UBS AM (a distinct business unit of UBS Asset Management Americas LLC) slashing its position by ‑75.8 %, offloading 13,533,313 shares worth roughly $1.12 billion.
- GQG Partners LLC initiating a new (+inf %) stake of 8,116,278 shares, valued at about $674 million.
- Citadel Advisors LLC more than tripling its exposure with a +1033.0 % increase, adding 6,503,526 shares (~$540 million).
- BlackRock, Inc. trimming its stake by ‑12.0 %, removing 6,080,951 shares (~$505 million).
- FMR LLC cutting holdings by ‑60.9 %, disposing of 5,587,444 shares (~$464 million).
- Qube Research & Technologies Ltd. and Pacer Advisors, Inc. each liquidating their entire positions (‑100 %), representing roughly $191 million and $182 million, respectively.
These divergent actions highlight that while some large investors are reducing exposure—perhaps due to valuation concerns or sector rotation—others are aggressively building positions, betting on CTSH’s growth prospects in digital transformation, cloud services, and AI‑enabled offerings.
Analyst Ratings Summary
Wall Street’s analyst community has issued a uniformly bullish outlook for CTSH over the past several months. Four firms have published ratings, all of which fall within the buy/overweight/outperform spectrum, with no sell ratings recorded. The specific ratings include:
- William Blair: “Outperform” (11/21/2025)
- Wells Fargo: “Overweight” (10/30/2025)
- JP Morgan: “Overweight” (10/30/2025)
- Guggenheim: “Buy” (10/21/2025)
The absence of any negative or neutral assessments suggests that analysts collectively anticipate CTSH will outperform its peers, driven by factors such as strong demand for IT outsourcing, ongoing cost‑optimization initiatives, and potential upside from emerging technologies.
Price Targets and Consensus
Consistent with the favorable ratings, twelve analysts have supplied price targets for CTSH within the last six months. The median target stands at $83.0, implying a moderate upside from the stock’s current trading level (which, based on the insider sale prices, appears to be in the low‑$70s range). Individual targets vary as follows:
- Kevin Mcveigh (UBS): $64.0 (04/13/2026)
- David Koning (Baird): $72.0 (04/10/2026)
- Steven Wahrhaftig (Wedbush): $61.0 (04/09/2026)
- Bryan Keane (Citigroup): $68.0 (04/07/2026)
- Bryan C. Bergin (TD Cowen): $71.0 (03/13/2026)
- James Faucette (Morgan Stanley): $82.0 (02/05/2026)
- Daniel R. Perlin (RBC Capital): $88.0 (02/05/2026)
The spread—from a low of $61.0 to a high of $88.0—reflects differing views on the pace of revenue recovery, margin expansion, and macro‑economic headwinds affecting discretionary IT spending. Nonetheless, the clustering of most targets in the $68‑$82 band reinforces a generally optimistic sentiment.
Caveats and Disclaimer
The figures presented herein are estimates derived from Quiver Quantitative’s analysis of SEC filings, insider transaction reports, institutional holdings data, and analyst publications. While every effort has been made to ensure accuracy, parsing errors, ticker‑mapping mistakes, or reporting delays may affect the precision of the numbers. Readers should treat the compensation estimate, insider trade volumes, hedge‑fund move magnitudes, and price targets as approximations intended for informational purposes only. This content does not constitute financial advice, investment recommendation, or an invitation to buy or sell any security. For definitive data, consult the original SEC DEF14A filing, the companies’ official disclosures, and the respective analysts’ reports. Additionally, past performance or insider activity is not indicative of future results, and investors should conduct their own due diligence before making any investment decisions.